Trial · NCT06882122
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122, Recruiting, IRCCS National Neurological Institute "C. Mondino" Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine. Trials, record NCT06882122. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06882122
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
- NCT number
- NCT06882122
- Status
- Recruiting
- Enrollment
- 30 participants, estimated
- Lead sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Conditions
- Migraine Disorder, Episodic Migraine
- Interventions
- Atogepant 60 mg
- First posted
- 2025-03-18
- Last updated
- 2025-03-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Temporal summation threshold of the RIII reflex (continuos variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Temporal summation threshold of the RIII reflex will be used to assess central sensitization after 3 months of treatment with atogepant 60 mg/day compared to baseline. |
| Primary | MAGL gene expression (continuos variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in MAGL gene expression after 3 months of treatment with atogepant 60 mg/day |
| Secondary | Habituation index of the nociceptive Blink Reflex (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | "Habituation index" of the nociceptive Blink Reflex will be used to evaluate difference in brainstem habituation after three months of treatment with atogepant 60mg. |
| Secondary | Habituation of the visual evoked potential (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Habituation of the visual evoked potential, assessed through P100 amplitude between the last and first block, will be used to assess changes in cortical habituation after three months of atogepant |
| Secondary | Functional brain connectivity (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in functional brain connectivity, assessed through HD-EEG after 3 months of treatment with atogepant 60 mg/day. |
| Secondary | FAAH gene expression (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in FAAH gene expression after 3 months of treatment with atogepant 60 mg/day. |
| Secondary | Plasma levels of CGRP (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in plasma levels of CGRP after 3 months of treatment with atogepant 60 mg/day. |
| Secondary | Plasma levels of PACAP (continuous variable) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in plasma levels of PACAP after 3 months of treatment with atogepant 60 mg/day. |
| Secondary | Gene expression of miR-382-5p, miR-34a-5p, and miR-155 (continuous variables) | Baseline (T0) - three months of atogepant 60 mg treatment (T1) | Changes in the gene expression of miR-382-5p, miR-34a-5p, and miR-155 after 3 months of treatment with atogepant 60 mg/day at the level of peripheral polymorphonuclear cells (PBMCs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06882122
GET https://conductscience.org/api/trials/v1/NCT06882122/registered